Mariposa is developing an innovative solution to treat the rare skin condition epidermolysis bullosa simplex (EBS). The company is a spin out from Neem Biotech, based in Wales, which has a long history in pharmaceutical research and has extensive capabilities to develop commercially viable solutions for serious healthcare challenges.

about mariposa about mariposa

About Mariposa

Developing a novel topical treatment for patients with epidermolysis bullosa (EBS)

mariposa science mariposa science

The Science

Grounded on unique expertise in ajoene chemistry and its biological activities

mariposa collaboration mariposa collaboration

Collaborate with us

Join in to innovate with us and to find a new treatment for EBS patients

chemical-sign
Latest News
Jun 25, 2020

Mariposa Therapeutics, a new private biotech company developing a novel topical treatment for patients with epidermolysis bullosa simplex (EBS) was established as a spin out from Neem Biotech, a company focused on the discovery of anti-virulence and anti-bacterial molecules utilising its...

Partners